Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional)

Active
Yes
Status
Posted
Published Date
April 29th, 2024
Close Date
August 13th, 2024
Opportunity No.
RFA-MH-25-185

Agency

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Income Security and Social Services

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Summary

The National Institutes of Health (NIH) has posted a grant opportunity titled "Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Optional)". This grant aims to support research that enhances the capacity, transformation, and scalability of HIV testing, prevention, and care services provided by pharmacists and pharmacies in both US and global settings. The goal is to develop training curricula that enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver a comprehensive range of HIV services with ease, equity, and effectiveness. The grant utilizes the R01 grant mechanism, while the RFA-MH-25-186 utilizes the R21 mechanism. Projects that lack preliminary data or propose to pilot a novel intervention may be more suitable for the R21 mechanism, while applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), non-domestic (non-U.S.) entities (Foreign Organizations), regional organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territories or Possessions. The closing date for applications is August 13, 2024. For more information and to apply, visit the following link: http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-185.html. For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

Description

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit research designed to capacitate, transform, and scale the delivery of HIV testing, prevention, and care services through pharmacists and pharmacies in US and/or global settings. This includes theadvancement of training curricula to enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver the spectrum of needed HIV services with ease, equity, and effectiveness. This NOFO uses the R01 grant mechanism, while RFA-MH-25-186 uses the R21 mechanism. Projects that lack preliminary data or that propose to pilot a novel intervention may be most appropriate for the R21 mechanism. Applications with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism.

Contact Information

Opportunity Lifecycle

Title
Type
Grant

Similar Opportunities

Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) has posted a grant opportunity titled "Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)". This grant aims to support research that enhances the capacity, transformation, and scalability of HIV testing, prevention, and care services provided by pharmacists and pharmacies in both US and global settings. The goal is to develop training curricula that enable pharmacy students, pharmacists, pharmacies, and pharmacy systems to deliver a comprehensive range of HIV services with ease, equity, and effectiveness. The R21 grant mechanism will be used for projects that lack preliminary data or propose to pilot a novel intervention. On the other hand, projects with preliminary data and those proposing large-scale clinical trials or longitudinal analyses should consider using the R01 mechanism. The grant does not require cost sharing or matching. The eligible applicants include various institutions and organizations such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The close date for this grant opportunity is August 13, 2024. For more information and to apply, visit the following link: [Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Optional)](http://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-186.html). For any inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "High Priority HIV and Substance Use Research (R01 Clinical Trial Optional)". This grant aims to support high priority research at the intersection of HIV and substance use. The funding is open to both individual researchers and research teams, and it includes all areas of research from basic science to clinical and implementation research. The goal is to encourage innovative research projects that have the potential to open new areas of HIV/AIDS research and/or lead to new avenues for prevention, treatment, and cure of HIV among people who use drugs (PWUD). The grant requires a detailed research plan, preliminary data, and a clear description of the nexus with substance use. The funding opportunity is part of the National Institutes of Health's HIV/AIDS Research Priorities. Eligible applicants include various institutions and organizations, such as Alaska Native and Native Hawaiian Serving Institutions, Faith-based or Community-based Organizations, and U.S. Territories or Possessions. The deadline for applications is August 2, 2024. For more information and to apply, visit the following website: [http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-040.html](http://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-040.html).
Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)
National Institutes of Health
The National Institutes of Health (NIH) is offering a grant opportunity titled "Advancing HIV/AIDS Research within the Mission of the NIDCD (R01 Clinical Trial Optional)". This grant aims to stimulate HIV/AIDS research within the scientific mission areas of the National Institute on Deafness and Other Communications Disorders (NIDCD). The grant is focused on addressing high priority HIV/AIDS research outlined by the NIH Office of AIDS Research (OAR) in the areas of hearing, balance, taste, smell, voice, speech, or language. The grant does not require cost sharing or matching requirements and is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Eligible Agencies of the Federal Government, Faith-based or Community-based Organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Indian/Native American Tribal Governments (Other than Federally Recognized), Non-domestic (non-U.S.) Entities (Foreign Organizations), Regional Organizations, Tribally Controlled Colleges and Universities (TCCUs), and U.S. Territory or Possession. The grant opportunity is currently open and the closing date for applications is January 7, 2026. For more information and to apply, please visit the following link: [Advancing HIV/AIDS Research Grant](http://grants.nih.gov/grants/guide/pa-files/PAR-23-099.html).
Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)
National Institutes of Health
The National Institutes of Health is offering a grant opportunity titled "Development and Testing of Novel Interventions to improve HIV Prevention, Treatment, and Program Implementation for People Who Use Drugs (R34 Clinical Trial Required)". This grant aims to support formative research, intervention development, and pilot-testing of interventions that target HIV prevention, treatment, or services research for people who use drugs. The grant seeks to explore the feasibility, tolerability, acceptability, and safety of novel or adapted interventions, including behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches. The goal is to prevent the acquisition and transmission of HIV infection and improve clinical outcomes for persons living with HIV. The grant does not require cost sharing or matching and falls under the category of health funding activity. The maximum award ceiling is $225,000. The grant is open to various eligible applicants, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions, eligible agencies of the Federal Government, faith-based or community-based organizations, Hispanic-serving Institutions, Historically Black Colleges and Universities, Indian/Native American Tribal Governments, non-domestic entities, regional organizations, Tribally Controlled Colleges and Universities, and U.S. Territories or Possessions. The closing date for applications is January 7, 2025. For more information and to apply, visit the following link: [http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html](http://grants.nih.gov/grants/guide/pa-files/PA-21-205.html). For any issues or inquiries, please contact the NIH OER Webmaster at grantsinfo@nih.gov.